Sökning: onr:"swepub:oai:gup.ub.gu.se/56090" >
Cardiovascular risk...
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study
-
Julius, S. (författare)
-
Alderman, M. H. (författare)
-
Beevers, G. (författare)
-
visa fler...
-
- Dahlöf, Björn, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
Devereux, R. B. (författare)
-
Douglas, J. G. (författare)
-
Edelman, J. M. (författare)
-
Harris, K. E. (författare)
-
Kjeldsen, S. E. (författare)
-
Nesbitt, S. (författare)
-
Randall, O. S. (författare)
-
Wright, J. T., Jr. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2004
- 2004
- Engelska.
-
Ingår i: J Am Coll Cardiol. - 0735-1097. ; 43:6, s. 1047-55
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- OBJECTIVES: We report on a subanalysis of the effects of losartan and atenolol on cardiovascular events in black patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. BACKGROUND: The LIFE study compared losartan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy (LVH). Overall, the risk of the primary composite end point (cardiovascular death, stroke, myocardial infarction) was reduced by 13% (p = 0.021) with losartan, with similar blood pressure (BP) reduction in both treatment groups. There was a suggestion of interaction between ethnic background and treatment (p = 0.057). METHODS: Exploratory analyses were performed that placed LIFE study patients into black (n = 533) and non-black (n = 8,660) categories, overall, and in the U.S. (African American [n = 523]; non-black [n = 1,184]). RESULTS: A significant interaction existed between the dichotomized groups (black/non-black) and treatment (p = 0.005); a test for qualitative interaction was also significant (p = 0.016). The hazard ratio (losartan relative to atenolol) for the primary end point favored atenolol in black patients (1.666 [95% confidence interval (CI) 1.043 to 2.661]; p = 0.033) and favored losartan in non-blacks (0.829 [95% CI 0.733 to 0.938]; p = 0.003). In black patients, BP reduction was similar in both groups, and regression of electrocardiographic-LVH was greater with losartan. CONCLUSIONS: Results of the subanalysis are sufficient to generate the hypothesis that black patients with hypertension and LVH might not respond as favorably to losartan-based treatment as non-black patients with respect to cardiovascular outcomes, and do not support a recommendation for losartan as a first-line treatment for this purpose. The subanalysis is limited by the relatively small number of events.
Nyckelord
- African Continental Ancestry Group
- Aged
- Aged
- 80 and over
- Antihypertensive Agents/administration & dosage/*therapeutic use
- Asian Continental Ancestry Group
- Atenolol/administration & dosage/*therapeutic use
- Blood Pressure/drug effects
- Drug Therapy
- Combination
- Europe
- European Continental Ancestry Group
- Female
- Humans
- Hypertension/complications/genetics/mortality/*prevention & control
- Hypertrophy
- Left Ventricular/*complications
- Losartan/administration & dosage/*therapeutic use
- Male
- Middle Aged
- Treatment Outcome
- United States
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Julius, S.
-
Alderman, M. H.
-
Beevers, G.
-
Dahlöf, Björn, 1 ...
-
Devereux, R. B.
-
Douglas, J. G.
-
visa fler...
-
Edelman, J. M.
-
Harris, K. E.
-
Kjeldsen, S. E.
-
Nesbitt, S.
-
Randall, O. S.
-
Wright, J. T., J ...
-
visa färre...
- Artiklar i publikationen
-
J Am Coll Cardio ...
- Av lärosätet
-
Göteborgs universitet